# US 2004/0019103 A1 · Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019103 A1
- Document ID: US20040019103A1
- Status: Published application
- Kind: A1
- Application number: 10/618,157
- Filed: 2003-07-10
- Published: 2004-01-29
- Earliest claimed: 1995-11-02
- Assignees: Biorex Research & Development Co.
- Inventors: Laszlo Vigh; Peter Literati Nagy; Jeno Szilbereky; Laszlo Urogdi; Andrea Jednakovits; Laszlo Jaszlits; Katalin Biro; Ede Marvanyos; Mihaly Barabas; Erzsebet Hegedus; Laszlo Koranyi; Maria Kurthy; Gabor Balogh; Ibolya Horvath; Zsolt Torok; Eva Udvardy; Gyorgy Dorman; Denes Medzihradszky; Bea Mezes; Eszter Kovacs; Erno Duda; Beatrix Farkas; Attila Glatz
- Web page: https://patentgrep.com/patent/US20040019103A1

## CPC

- C07D 213/78: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/16: Central respiratory analeptics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 259/02: with replacement of the other oxygen atom of the carboxyl group by halogen atoms
- C07C 259/18: having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
- C07C 275/64: having nitrogen atoms of urea groups singly-bound to oxygen atoms
- C07C 279/18: having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 215/54: attached in position 3
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 295/088: to an acyclic saturated chain
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

## Claims

### Claim 1

A method of increasing expression of a molecular chaperon by an eukaryotic cell comprising:
treating an eukaryotic cell of a living mammalian organism that is exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury with an effective amount of a chemical compound to increase the expression of the molecular chaperon by the cell beyond the amount induced by the physiological stress, wherein the chemical compound is one or more of a hydroxylamine derivative represented by formula (II),
3
or a salt thereof or any optically active streoisomer thereof, wherein
A is an alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,
Z is a covalent bond, oxygen or ═NR3, wherein R3 is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl and aralkyl substituted in the aryl and/or alkyl moiety,
R is alkyl or substituted alkyl, and
X is oxygen, imino or substituted imino group and R′ is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl having substituted aryl or alkyl moiety, acyl or substituted acyl group.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the cell is treated before the physiological stress.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the cell is treated after the physiological stress.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mammalian cell is a human cell.

### Claim 5 (depends on 1)

The method of claim 1 wherein the cell is a neuronal cell, muscle cell, vessel wall cell, epithelial cell or a cell of the immune system.

### Claim 6 (depends on 1)

The method of claim 1 wherein the physiological stress is metabolic, oxidative or local mechanical stress or a stress caused by hypoxia, heat shock, radiation or toxic materials.

### Claim 7 (depends on 1)

The method of claim 1 wherein the physiological stress causes an increase of reactive free radicals or a cytokine present in the area surrounding the cell.

### Claim 8 (depends on 1)

The method of claim 1 wherein one or more of the skin or mucosal disease is caused by dermatosis or ulcerous disease of the gastrointestinal system provoked by physiological stress.

### Claim 9 (depends on 1)

The method of claim 1 wherein the molecular chaperon is a heat shock protein (hsp).

### Claim 10 (depends on 9)

The method of claim 9 wherein the hsp is hsp70 or hsp72.

### Claim 11

A method of increasing activity of a molecular chaperon in an eukaryotic cell that is exposed to a physiological stress comprising:
treating the cell that is exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury with an effective amount of a chemical compound to increase the activity of the molecular chaperon in the cell beyond the amount induced by the physiological stress, wherein the chemical compound is one or more of a hydroxylamine derivative represented by formula (II),
4
or a salt thereof or an optically active stereoisomer thereof,
wherein A is an alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,
Z is a covalent bond, oxygen or ═NR3, wherein R3 is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl and aralkyl substituted in the aryl and/or alkyl moiety,
R is an alkyl or substituted alkyl,
X is oxygen, imino or substituted imino group,
and R′ is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl having substituted aryl or alkyl moiety, acyl or substituted acyl group.

### Claim 12 (depends on 11)

The method of claim 11 wherein the physiological stress is metabolic, oxidative or local mechanical stress or a stress caused by hypoxia, heat shock, radiation or toxic materials.

### Claim 13 (depends on 11)

The method of claim 11 wherein the physiological stress causes an increase of reactive free radicals or a cytokine present in the area surrounding the cell.

### Claim 14 (depends on 11)

The method of claim 11 wherein one or more of the skin or mucosal disease is caused by dermatosis or ulcerous disease of the gastrointestinal system provoked by physiological stress.

### Claim 15 (depends on 11)

The method of claim 11 wherein the molecular chaperon is a heat shock protein (hsp).

### Claim 16 (depends on 15)

The method of claim 15 wherein the hsp is hsp70 or hsp72.

### Claim 17

A method of treating a disease connected with the function of the chaperon system or associated with the injury of the membrane of a cell or cell organellum or preventing the same which comprises:
administering to a host that has been exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury an effective amount of a chemical compound to increase the expression of a molecular chaperon by cells of the host beyond an amount induced by the physiological stress to ameliorate the effect caused by the pathological condition in the organism, wherein the chemical compound is one or more of a hydroxylamine derivative represented by formula (II),
5
or a salt thereof or an optically active stereoisomer thereof, wherein
A is alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,
Z is a covalent bond, oxygen or ═NR3, wherein R3 is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl and aralkyl substituted in the aryl and/or alkyl moiety,
R is an alkyl or substituted alkyl, and
X is oxygen, imino or substituted imino group and R′ is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl having substituted aryl or alkyl moiety, acyl or substituted acyl group.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pathological condition is selected from the group consisting of a neoplastic disease, an infection caused by a pathogenic microorganism, an autoimmune disease and dermatosis.

### Claim 19 (depends on 17)

The method of claim 17 wherein the host is a human organism.

### Claim 20 (depends on 17)

The method according to claim 17, wherein
R is alkyl or substituted alkyl, and
a) Z is chemical bond and X is oxygen, or
b) Z is chemical bond and X is ═NR4 wherein R4 is H or unsubstituted or substituted alkyl or cycloalkyl, or
c) Z is oxygen and X is oxygen, or
d) Z is oxygen and X is ═NR4 wherein R4 is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl, unsubstituted or substituted aryl, or heteroaryl, or
e) Z is ═NR3, wherein R3 is H, unsubstituted or substituted alkyl, aryl or aralkyl, and X is oxygen, or
f) Z is ═NR3, wherein R3 is H, unsubstituted or substituted alkyl, aryl or aralkyl and X is ═NR4, wherein R4 is H, unsubstituted or substituted alkyl or aralkyl, or cycloalkyl.

### Claim 21 (depends on 20)

The method of claim 20 wherein R is an ω-amino-alkyl which may be substituted on the amino and/or alkyl group, and wherein the alkyl chain contains 3 to 8 carbon atoms and is straight or branched, and can be substituted with hydroxy or acyloxy.

### Claim 22 (depends on 20)

The method of claim 20 wherein R is an ω-amino-alkyl mono- or disubstituted on the amino, wherein the disubstituted amino substituents, are independently one or two straight or branched alkyl or cycloalkyl, or the disubstituted amino substituents, together with the nitrogen atom attached thereto, form a 3 to 7-membered saturated hetero ring, which may contain additional hetero atom(s).

### Claim 23 (depends on 20)

The method according to claim 20, wherein
Z is a chemical bond,
X is oxygen,
R′ is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, and
A is unsubstituted or substituted aryl or aralkyl, or heteroaryl.

### Claim 24 (depends on 23)

The method of claim 23 wherein A is
a) phenyl, or
b) phenyl substituted with one or more alkyl, haloalkyl or alkoxy,
c) aralkyl, or
d) aralkyl substituted in one or more of the aryl or alkyl moiety, or
e) N-containing heteroaryl, or
f) S-containing heteroaryl.

### Claim 25 (depends on 20)

The method according to claim 20, wherein
Z is chemical bond,
X is ═NR4, wherein R4 is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, or cycloalkyl,
R′ is unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl or aralkyl substituted in the aryl and/or alkyl moiety, and
A is aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, unsubstituted or substituted aryl or heteroaryl.

### Claim 26 (depends on 25)

The method of claim 25 wherein A is
a) phenylalkyl, or
b) phenylalkyl substituted with one or more alkoxy in the phenyl moiety, or
c) phenyl, or
d) phenyl substituted with one or more alkyl, haloalkyl or nitro, or
e) naphtyl, or
f) N-containing heteroaryl, or
g) an S-containing heteroaryl.

### Claim 27 (depends on 20)

The method according to claim 20 wherein
Z is oxygen,
X is oxygen,
R′ is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, and
A is unsubstituted or substituted straight or branched alkyl, aralkyl, or aralkyl substituted in one or both of the aryl or alkyl moiety.

### Claim 28 (depends on 20)

The method according to claim 20 wherein Z is oxygen and X is ═NR4, wherein R4 is unsubstituted or substituted straight or branched alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, unsubstituted or substituted phenyl or unsubstituted or substituted heteroaryl, and R′ is unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety.

### Claim 29 (depends on 20)

The method according to claim 20, wherein
Z is ═NR3,
R3 is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety,
X is oxygen,
R′ is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, or acyl, and
A is unsubstituted or substituted alkyl, aralkyl, aryl or heteroaryl or cycloalkyl.

### Claim 30 (depends on 29)

The method according to claim 29 wherein A is
a) unsubstituted or substituted straight or branched alkyl which contains 4 to 12 carbon atoms, or
b) cycloalkyl, or
c) unsubstituted or substituted phenylalkyl, or
d) phenyl, or
e) phenyl substituted with one or more halo, alkyl, haloalkyl, alkoxy or nitro, or
f) an N-containing heterocyclic group.

### Claim 31 (depends on 20)

The method according to claim 20, wherein
Z is ═NR3, wherein R3 is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety,
X is ═NR4, wherein R4 is H, unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety or cycloalkyl, and
R′ is unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, and
A is unsubstituted or substituted straight or branched alkyl or unsubstituted or substituted aryl.

### Claim 32

Hydroxylamine derivatives of the formula (II)
6
wherein
a) X is oxygen,
A is C1-20 straight or branched alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, naphtyl or N-containing heteroaromatic group,
Z is chemical bond,
R′ is H, C1-4 alkyl or aralkyl, and
R is a group of the formula (b),
7
where R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H, k is 1, 2 or 3, and m is 1, 2, or 3, with the proviso that when A is other than alkyl and R′ is H, Y6 is H, or
b) X is ═NR4, wherein R4 is H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl,
A is unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, or cycloalkyl,
Z is chemical bond, oxygen or ═NR3, wherein R3 is H or unsubstituted or substituted alkyl,
R′ is unsubstituted or substituted alkyl or unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, and
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H or unsubstituted or substituted alkylcarbonyl or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
c) X is oxygen,
A is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl,
Z is oxygen,
R′ is alkyl or aralkyl,
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H or unsubstituted or substituted alkylcarbonyl or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
d) X is oxygen,
Z is ═NH and
A is unsubstituted or substituted alkyl, cycloalkyl, unsubstituted or substituted aralkyl, phenyl or phenyl substituted with halo, alkyl, haloalkyl, alkoxy or nitro,
R′ is alkyl or aralkyl, and
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OH, k is 1, 2 or 3, and m is 1, 2 or 3.

### Claim 33 (depends on 32)

The hydroxylamine derivatives of claim 32, wherein A is phenyl, substituted phenyl or phenylalkyl.

### Claim 34

Pharmaceutical composition, and said composition's pharmaceutically acceptable carriers and auxiliaries, for the treatment of cardiovascular, vascular, cerebral, allergic, immune, autoimmune diseases, diseases caused by viral or bacterial infections, tumorous, skin or mucosal diseases, wherein the said composition contains 0,5 to 99,5% by weight of a hydroxylamine compound of the formula (II)
8
wherein
a) X is oxygen,
A is C1-20 straight or branched alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, naphtyl or N-containing heteroaromatic group,
Z is chemical bond,
R is H, C1-4 alkyl or aralkyl, and
R is a group of the formula (b),
9
where R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H, k is 1, 2 or 3, and m is 1, 2, or 3, with the proviso that when A is other than alkyl and R′ is H, Y6 is H, or
b) X is ═NR4, wherein R4 is H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl,
A is unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, or cycloalkyl,
Z is chemical bond, oxygen or ═NR3, wherein R3 is H or unsubstituted or substituted alkyl,
R′ is unsubstituted or substituted alkyl or unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, and
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H or unsubstituted or substituted alkylcarbonyl or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
c) X is oxygen,
A is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl,
Z is oxygen,
R′ is alkyl or aralkyl,
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OR7 wherein R7 is H or unsubstituted or substituted alkylcarbonyl or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
d) X is oxygen,
Z is ═NH and
A is unsubstituted or substituted alkyl, cycloalkyl, unsubstituted or substituted aralkyl, phenyl or phenyl substituted with halo, alkyl, haloalkyl, alkoxy or nitro,
R′ is alkyl or aralkyl, and
R is a group of the formula (b), wherein R5 and R6 are independently H, straight or branched alkyl, or cycloalkyl, or R5 and R6, when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring, Y6 is H or —OH, k is 1, 2 or 3, and m is 1,2 or 3.
